Critical Contrast: Palatin Technologies (PINK:PTNT) vs. Comera Life Sciences (NASDAQ:CMRA)

Comera Life Sciences (NASDAQ:CMRA) and Palatin Technologies (PINK:PTNT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Institutional & Insider Ownership

11.5% of Palatin Technologies shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 7.1% of Palatin Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Comera Life Sciences and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Palatin Technologies	N/A	N/A	-365.57%

Earnings & Valuation

This table compares Comera Life Sciences and Palatin Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	($0.49)	N/A
Palatin Technologies	$4.49 million	32.44	-$29.74 million	($1.55)	-3.61

Comera Life Sciences has higher earnings, but lower revenue than Palatin Technologies. Palatin Technologies is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Comera Life Sciences has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Comera Life Sciences and Palatin Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Comera Life Sciences	0	0	0	0	0.00
Palatin Technologies	0	0	1	0	3.00

Palatin Technologies has a consensus price target of $350.00, suggesting a potential upside of 6,150.00%. Given Palatin Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Palatin Technologies is more favorable than Comera Life Sciences.

Summary

Comera Life Sciences beats Palatin Technologies on 6 of the 11 factors compared between the two stocks.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.